Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue: 2014-2018

Historic Non-Current Deffered Revenue for ImmunityBio (IBRX) over the last 5 years, with Dec 2018 value amounting to $2.7 million.

  • ImmunityBio's Non-Current Deffered Revenue fell 17.62% to $2.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 million, marking a year-over-year decrease of 17.62%. This contributed to the annual value of $2.7 million for FY2018, which is 17.62% down from last year.
  • Latest data reveals that ImmunityBio reported Non-Current Deffered Revenue of $2.7 million as of FY2018, which was down 17.62% from $3.3 million recorded in FY2017.
  • ImmunityBio's Non-Current Deffered Revenue's 5-year high stood at $3.3 million during FY2017, with a 5-year trough of $521,000 in FY2014.
  • For the 3-year period, ImmunityBio's Non-Current Deffered Revenue averaged around $2.8 million, with its median value being $2.7 million (2018).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 187.10% in 2016, then decreased by 17.62% in 2018.
  • ImmunityBio's Non-Current Deffered Revenue (Yearly) stood at $521,000 in 2014, then spiked by 62.19% to $845,000 in 2015, then surged by 187.10% to $2.4 million in 2016, then skyrocketed by 37.06% to $3.3 million in 2017, then dropped by 17.62% to $2.7 million in 2018.